You Searched For "Abbvie" and got 20 results
Sort By:
2 mins read
Warren Buffett's Berkshire Hathaway sold Biogen, halved its Merck stake, and boosted its Kroger bet. Here's a closer look at its key trades in Q2.
Buffett's company established stakes in Merck, AbbVie, and Bristol Myers Squibb in the second half …
Theron Mohamed
2 mins read
Democrat Katie Porter accuses pharma CEO of inflating drug prices and 'lying' to patients and policymakers - all with the help of her whiteboard
Rep. Katie Porter, who sits on the House Oversight Committee, has become well-known for using her "…
Eliza Relman
2 mins read
Warren Buffett's Berkshire Hathaway plowed more than $5 billion into 4 pharma stocks last quarter. He's been teasing a bet on the sector for more than 20 years
"If we could buy a group of leading pharmaceutical companies at a below-market multiple, I think we…
Theron Mohamed
2 mins read
AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarter
The "Buffett Effect" kicked in after the famed investor disclosed about $6 billion in new pharmaceu…
Theron Mohamed
2 mins read
Warren Buffett's Berkshire Hathaway reveals $6 billion bet on AbbVie, Merck, Pfizer, and other 'big pharma' stocks
The famed investor's company disclosed more than $1.8 billion worth of stock in each of AbbVie, Mer…
Theron Mohamed
2 mins read
Abbvie is buying Allergan in a $63 billion pharma mega-deal
Biopharmaceuticals specialist Abbvie and drugmaker Allergan expect the merger to create a leading p…
Theron Mohamed
3 mins read
Meet the bankers involved in AbbVie's $63 billion bid for Botox-maker Allergan
Lysaght is a UK takeover specialist, Meilman is a managing director at the bank. Monaghan has advis…
Lydia Ramsey
1 min read
Allergan spikes 30% after AbbVie agrees to buy the Botox-maker for $63 billion
"With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, …
Daniel Strauss
1 min read
2 mins read
4 biotechs that could be the next takeout targets after AbbVie's $63 billion acquisition of Allergan
There is, of course, no guarantee of future dealmaking, but this latest acquisition could foreshado…
Clarrie Feinstein,Emma Court
2 mins read
Wall Street Payday: The banks on the massive AbbVie-Allergan deal stand to make $183 million
According to research provider Dealogic, AbbVie's lead adviser Morgan Stanley, could stand to make …
Lydia Ramsey
3 mins read
AbbVie said that its $63 billion deal for Allergan has at least $2 billion in 'synergies.' That should make employees nervous.
Big companies often tout cost cuts as they make the case to Wall Street that they're striking smart…
Clarrie Feinstein
2 mins read
A cancer drug that AbbVie acquired in a $10 billion deal is looking more and more like a failure
The latest evidence piling up against the drug came on Wednesday afternoon, as the pharmaceutical c…
Emma Court
3 mins read
AbbVie's $63 billion mega-deal for Botox-maker Allergan is the pharma industry's latest bet that bigger is better. But the deal is already facing big questions.
AbbVie didn't want to take "a lot of binary risks" such as researching new, experimental drugs, "be…
Emma Court
3 mins read
Drugmaker AbbVie's stock gets slammed after FDA warning
Patients taking these medicines should contact their health care professional immediately if they d…
Julia La Roche
6 mins read
AbbVie spent billions on a buzzy Silicon Valley cancer drug company. Now Wall Street's calling the deal a 'dud.'
"Our acquisition of Stemcentrx provided a novel drug discovery engine, Rova-T, and a pipeline of se…
Lydia Ramsey
4 mins read
Here's the cancer data that led AbbVie to make the second-largest acquisition in the history of venture capital
The Stemcentrx drug that's farthest along thus far is called rovalpitzumab tesirine, or Rova-T. It'…
Lydia Ramsey
3 mins read
Here's why pharma giant AbbVie coughed up $10 billion to buy a startup you've never heard of
To get a sense of why AbbVie went after the company and its cancer stem cell-targeting drug pipelin…
Lydia Ramsey
2 mins read
Morgan Stanley just added these 3 safe stocks to their 'buy' list with the market expected to stay choppy
Morgan Stanley suggested PEG, ABBV, and NOC as stocks to buy amid market uncertainty.
Filip De Mott
2 mins read
A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year
Bob Duggan, 80, has gone from baking cookies to building robots, investing in biotech companies, an…